Endpoints News
Endpoints News reports Lilly's direct-to-patient sales model, built on Americans paying hundreds a month, is now becoming part of its plans overseas.
Recap by typeshit. Full story at Endpoints News.
Obesity specialist Dr. Alexandra Sowa says long-term use makes cost the flashpoint, as insurers and employers scale back coverage and Medicare benefits face a 2027 question.
With 30% of covering employers weighing cuts, Wegovy and Zepbound users should check their plans now. Includes current self-pay prices and tips for appeals.
West Pharmaceutical shares are up about 20% since CNBC flagged the valuation in August, and the latest earnings give it reasons to expect further gains.
GEN ranks the best-selling drugs by 2025 sales, and Lilly's weight loss shot outpaced names like Merck's Keytruda on growth.
A woman with four triglyceride-driven pancreatitis episodes came off insulin and had none for 12 months. The authors stress it shows association, not cause.
An FDA compounding advisory committee backed six peptides for compounding. Frank says controlled human data is thin and reported benefits are mostly anecdotal.
Loading…